Lauren C. Leiman, Executive Director of BLOODPAC, and Mary Royal, a breast cancer survivor and ctDNA testing advocate, sat down with Believe in Progress: An #AACR Foundation Podcast host Mitchell Stoller to discuss the evolving role of liquid biopsy in cancer care.

In this blog we recap our Early Detection & Screening (ED&S) Working Group’s summer seminar “Performance with Purpose: Metrics that Inform Clinical and Public Health Decisions,” which took place virtually on August 20 at 11:00 AM ET.

At the 2024 annual meeting of the American Association for Cancer Research (AACR), BLOODPAC’s Early Detection and Screening Working Group (ED&S WG) hosted a session focusing on cancer risk and risk assessment for liquid biopsy-based single- and multi-cancer screening.

Lauren Leiman, Executive Director at BLOODPAC and Dr. Emma Alme, Public Policy Director at Guardant Health sat down with JCO Podcast host, Dr. Rafeh Naqash to discuss accessibility to liquid biopsy for cancer, potential barriers and proposed solutions.

In this article, we explore the identification, characterization, analysis, and clinical applications of circulating tumor cells in blood-based liquid biopsy for cancer management.

Advances in cancer detection have historically lagged behind the development of new cancer treatments. Liquid biopsy is poised to change this. The development of blood-based cancer detection assays in the past several years has led to numerous high-profile studies and hundreds of thousands of individuals enrolled in clinical trials.

Any cancer diagnosis is devastating, but the discovery of a brain tumor comes with a unique set of challenges for both patient and doctor. In this article, we discuss the potential role of liquid biopsy for management of brain cancer, current research in this space, and remaining questions in the field.